Indaptus Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGIndaptus Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings contraction of 144% provides fundamental context to the price action. However, price is extended 31% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.17 | +7.40% | ABOVE |
| 50 SMA | $2.61 | +30.57% | ABOVE |
| 100 SMA | $2.24 | +52.57% | ABOVE |
| 150 SMA | $2.31 | +47.60% | ABOVE |
| 200 SMA | $2.52 | +35.24% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is INDP in an uptrend right now?
INDP has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is INDP overbought or oversold?
INDP's RSI (14) is 53. The stock is in neutral territory, neither overbought nor oversold.
Is INDP outperforming the market?
INDP has a Relative Strength (RS) Rating of 83 out of 99. Yes, INDP is a market leader, outperforming 83% of all stocks over the past 12 months.
Where is INDP in its 52-week range?
INDP is trading at $3.41, which is 25% of its 52-week high ($13.40) and 20% above its 52-week low ($0.93).
How volatile is INDP?
INDP has a Beta of 2.70 and 52-week volatility of 145%. It's more volatile than the S&P 500 - expect bigger swings.